Please login to the form below

Not currently logged in
Email:
Password:

myeloma

This page shows the latest myeloma news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

and a 56% complete response rate in a heavily pre-treated multiple myeloma population. ... been able to go for over a year with no additional myeloma therapy and tolerable adverse effects.”.

Latest news

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    abaloparatide) and confirming its earlier rejection of Pharma Mar’s Aplidin (plitidepsin) as a treatment for multiple myeloma.

  • Celgene’s triple multiple myeloma therapy clears phase III trial Celgene’s triple multiple myeloma therapy clears phase III trial

    Celgene’ s triple multiple myeloma therapy clears phase III trial. The biotech says the combo hit its OPTIMISMM primary endpoint. ... Celgene are now hoping that its new triple therapy has the potential to boost sales even further in the multiple

  • Amgen set for Kyprolis label boost after CHMP backing Amgen set for Kyprolis label boost after CHMP backing

    Amgen set for Kyprolis label boost after CHMP backing. Multiple myeloma treatment set to add new survival data. ... The Committee for Medicinal Products for Human Use (CHMP) has given the go-ahead for Amgen to add survival data to the labelling for its

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    There are some interesting wrinkles in the transaction. Juno’s second most advanced candidate is a B-cell maturation antigen (BCMA) targeting CAR-T - JCARH125 for multiple myeloma - which is a

  • Unsure on efficacy, NICE passes J&J’s Darzalex to CDF Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

    Johnson &Johnson’s multiple myeloma drug Darzalex has failed to win over NICE for a second time, but will be made available via the Cancer Drugs Fund (CDF) as an interim ... measure. The UK’s health technology assessment agency rejected Darzalex

More from news
Approximately 59 fully matching, plus 185 partially matching documents found.

Latest Intelligence

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two sessions.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

  • Lighting the way Lighting the way

    The independent review's final report emerged in October 2016, with potential implications for treatment access for a number of conditions, with myeloma, melanoma and dementia highlighted in the publication.

  • Deal Watch September 2016 Deal Watch September 2016

    Boehringer Ingelheim granted Amgen worldwide rights to BI 836909, a bispecific T cell engager designed to treat multiple myeloma.

  • Does safety sell medicines? Does safety sell medicines?

    Who would have thought 50 years ago that thalidomide would be back on the UK market helping patients with life-threatening multiple myeloma - possible due to a risk management programme centered

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics